Cancer Stem Cells: Targeting the Core of the Cancer
DOI:
https://doi.org/10.15173/m.v1i27.957Abstract
One of the major challenges faced after conventional treatment of cancer is a relapse of the cancer. Emerging research has led to the identification of cancer stem cells (CSCs) which evade conventional treatment and fuel the growth and metastasis of the tumour. CSCs comprise a relatively small population of the tumour but have considerable impact in the relapse of many cancers. Research in the past decade has been instrumental in the development of drugs that eliminate CSCs. This review attempts to provide an understanding of the formation and characteristics of CSCs as well as highlight three drug therapies that have shown potential for eradicating CSCs. Researchers believe that elimination of CSCs can allow for longer lasting or even permanent remission of cancer.
References
Becker AJ, McCulloch EA, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature. 1963 Feb 2 [cited 2014 Dec 2];197(4866):452–4.
Jordan CT, Guzman ML, Noble M. Cancer Stem Cells. N Engl J Med. 2006 Sept 21 [cited 2014 Nov 30];355(12):1253–62.
Guo W, Lasky JL, Wu H. Cancer stem cells. Pediatr Res [Internet]. 2006 Apr [cited 2014 Nov 6];59(4):59R–64R. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16549550
Al-Hajj M & Clarke MF. Self-renewal and solid tumor stem cells. Oncogene [Internet]. 2004 Sept 20 [cited 2014 Dec 4];23(43):7274-82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15378087
Rao MS & Mattson MP. Stem cells and aging : expanding the possibilities. Mech Ageing Dev [Internet]. 2000 Nov 22 [cited 2014 Dec 17];122:713–34.
Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Rev Cancer [Internet]. 2008 Oct [cited 2014 Dec 23];8(10):755–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18784658
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001 Nov [cited 2014 Dec 4];414:105–11.
Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med [Internet]. 2011 Mar [cited 2014 Dec 4];17(3):313–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21386835
Marchal JA, Carrasco E, Ramirez A, Jimenez G, Olmedo C, Peran M, et al. Bozepinib , a novel small antitumor agent , induces PKR-mediated apoptosis and synergizes with IFNα triggering apoptosis, autophagy and senescence. Drug Dev Ther [Internet]. 2013 Oct 25 [cited 2014 Dec 7];7:1301–13.
Ramírez A, Boulaiz H, Morata-tarifa C, Perán M, Jiménez G, Picon-ruiz M, et al. HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib. Oncotarget [Internet]. 2014 May 13 [cited 2014 Dec 7];5(11).
Verastem Incorporation [Internet]. Needham (MA): Verastem Incorporation; 2014 [cited 2014 November 25]. Available from: http://www.verastem.com
Keegan M, Ring JE, Kolev VN, Shapiro IM, Padval MV, Xu Q, et al. VS-6063 (Defactinib) targets mesothelioma cancer stem cells directly and through inhibition of tumor-associated macrophages and cytokine production. Annals of Oncology [Internet]. 2014 [cited 2014 Dec 16];25(4):543-563.
Zhang J, Hochwald SN. The role of FAK in tumor metabolism and therapy. Pharmacol Therapeut [Internet]. 2014 May [cited 2014 Dec 16];142(2):154–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24333503
Zhao X, Guan J-L. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliver Rev [Internet]. 2011 Jul 18 [cited 2014 Dec 21];63(8):610–5. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3132829&tool=pmcentrez&rendertype=abstract
Schultze A & Fiedler W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin Investig [Internet]. 2010 [cited 2014 Dec 16];19(6):777–88.
Koo KH, Kim H, Bae Y-K, Kim K, Park B-K, Lee C-H, et al. Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2. Cell Death Disease [Internet]. 2013 Jan [cited 2014 Dec 23];4(6):e693. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3702291&tool=pmcentrez&rendertype=abstract
Huczynski A. Salinomycin: a new cancer drug candidate. Chem Biology Drug Des [Internet]. 2012 Mar [cited 2014 Dec 24];79(3):235–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22145602
Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Bioph Res Co [Internet]. 2009 Oct 14 [cited 2014 Dec 25];390(3):743–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19835841
Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. PNAS [Internet]. 2011 Aug 9 [cited 2014 Dec 24];108(32):13253–7. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3156152&tool=pmcentrez&rendertype=abstract
Naujokat C & Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol [Internet]. 2012 Jan [cited 2014 Dec 30];2012:950658. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3516046&tool=pmcentrez&rendertype=abstract
Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res [Internet]. 2006 Oct 1 [cited 2014 Dec 5];66(19):9339–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16990346
Guan J. Role of focal adhesion kinase in integrin signaling. Int J Biochem Cell Biol [Internet]. 1997 Apr 14 [cited 2014 Dec 16];29(97):1085–96.
Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell stem cell [Internet]. 2007 Sep 13 [cited 2014 Dec 23];1(3):313–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18371365
Kroder G, Bossenmaier B, Kellerer M, Capp E, Stoyanov B, Mühlhöfer A, et al. Tumor necrosis factor-α and hyperglycemia-induced insulin resistance evidence for different mechanisms and different effects on insulin signaling. J Clin Invest [Internet]. 1995 Dec 14 [cited 2014 Dec 16];97:1471–7.
May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA. Epithelial – mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res. 2011 [cited 2014 Dec 23];13:202.
Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res [Internet]. 2005 July 1 [cited 2014 Dec 7];(13):5506–12.
Prince ME, Kaczorowski RSA, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. PNAS [Internet]. 2007 Jan 16 [cited 2014 Dec 4];104(3):973-978.
Rando TA. Stem cells, ageing and the quest for immortality. Nature [Internet]. 2006 Jun 29 [cited 2014 Dec 17];441(7097):1080–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16810243
Reya T & Clevers H. Wnt signalling in stem cells and cancer. Nature [Internet]. 2005 Apr 14 [cited 2014 Dec 23];434.
Rosen JM & Jordan CT. The increasing complexity of the cancer stem cell paradigm. NIH [Internet]. 2010 May 19 [cited 2014 Dec 6];324(5935):1670–3.
Schultze A, & Fiedler W. (2011). Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase. Anticancer Agents Med Chem. 2011 [cited 2014 Dec 12];11(7):593–599.
Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea--a paradigm shift. Cancer Res [Internet]. 2006 Feb 15 [cited 2014 Dec 14];66(4):1883–90; Available from: http://www.ncbi.nlm.nih.gov/pubmed/16488983
Zachary I. Focal adhesion kinase. Int J Biochem Cell Biol [Internet]. 1997 Jan 10 [cited 2014 Dec 16];29(I):929–34.
